Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on May 22, 2017 - 15:59 GMT

Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from a Phase 2 study evaluating the safety, efficacy and therapeutic dose range of MK-7264 (formerly AF- …

Distribution channels: Companies

Published on April 22, 2017 - 11:04 GMT

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C …

Distribution channels: Companies

Published on April 19, 2017 - 12:23 GMT

Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company’s established and investigational …

Distribution channels: Companies

Published on March 6, 2017 - 13:17 GMT

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing ...

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug …

Distribution channels: Companies

Published on February 26, 2017 - 17:43 GMT

Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of …

Distribution channels: Companies

Published on February 24, 2017 - 21:21 GMT

In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the …

Distribution channels: Companies

Published on February 14, 2017 - 22:28 GMT

Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational …

Distribution channels: Companies

Published on February 14, 2017 - 21:14 GMT

Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection,...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non- …

Distribution channels: Companies

Published on November 12, 2016 - 16:59 GMT

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in …

Distribution channels: Companies

Published on November 7, 2016 - 12:15 GMT

New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated …

Distribution channels: Companies

Published on November 2, 2016 - 20:49 GMT

Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small …

Distribution channels: Companies

Published on October 21, 2016 - 10:56 GMT

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with …

Distribution channels: Companies

Published on October 9, 2016 - 06:25 GMT

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months …

Distribution channels: Companies

Published on October 9, 2016 - 06:25 GMT

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the first-line treatment of patients …

Distribution channels: Companies

Published on October 8, 2016 - 12:49 GMT

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA® (pembrolizumab), …

Distribution channels: Companies

Published on October 8, 2016 - 06:20 GMT

New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy …

Distribution channels: Companies

Published on September 15, 2016 - 12:41 GMT

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and ...

KENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 …

Distribution channels: Companies

Published on September 2, 2016 - 11:07 GMT

Merck Provides Update on Odanacatib Development Program

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck’s investigational cathepsin K inhibitor for osteoporosis, and will not …

Distribution channels: Companies

Published on August 8, 2016 - 21:28 GMT

Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and …

Distribution channels: Companies

Published on August 5, 2016 - 12:32 GMT

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an …

Distribution channels: Companies